Douglas W. Wilmore
Keine laufenden Positionen mehr
Karriereverlauf von Douglas W. Wilmore
Ehemalige bekannte Positionen von Douglas W. Wilmore
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
EMI Holding, Inc.
EMI Holding, Inc. Pharmaceuticals: MajorHealth Technology EMI Holding, Inc. discovers, develops, and commercializes treatments and therapies for rare diseases. The firm also engages in the marketing and sale of NutreStore L-glutamine powder for oral solution, a treatment for short bowel syndrome and the sale of L-glutamine as a nutritional supplement under the brand name AminoPure. The company was founded by Yutaka Niihara in 1987 and is headquartered in Torrance, CA. | Direktor/Vorstandsmitglied | 03.05.2011 | 01.09.2011 |
Independent Dir/Board Member | 14.07.2011 | 01.09.2011 | |
Emmaus Medical, Inc.
Emmaus Medical, Inc. BiotechnologyHealth Technology Emmaus Medical, Inc. engages in the discovery, development and commercialization of treatments and therapies for rare diseases. Its current business is the late-stage development presently in Phase III clinical trials with the FDA of the amino acid L-glutamine as a prescription drug for the treatment of Sickle Cell Disease. The company was founded on December 20, 2000 and is headquartered in Torrance, CA. | Direktor/Vorstandsmitglied | 08.02.2010 | - |
Ausbildung von Douglas W. Wilmore
University of Kansas | Undergraduate Degree |
Washburn University | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 5 |
Operativ
Director/Board Member | 2 |
Undergraduate Degree | 2 |
Independent Dir/Board Member | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Emmaus Medical, Inc.
Emmaus Medical, Inc. BiotechnologyHealth Technology Emmaus Medical, Inc. engages in the discovery, development and commercialization of treatments and therapies for rare diseases. Its current business is the late-stage development presently in Phase III clinical trials with the FDA of the amino acid L-glutamine as a prescription drug for the treatment of Sickle Cell Disease. The company was founded on December 20, 2000 and is headquartered in Torrance, CA. | Health Technology |
EMI Holding, Inc.
EMI Holding, Inc. Pharmaceuticals: MajorHealth Technology EMI Holding, Inc. discovers, develops, and commercializes treatments and therapies for rare diseases. The firm also engages in the marketing and sale of NutreStore L-glutamine powder for oral solution, a treatment for short bowel syndrome and the sale of L-glutamine as a nutritional supplement under the brand name AminoPure. The company was founded by Yutaka Niihara in 1987 and is headquartered in Torrance, CA. | Health Technology |
- Börse
- Insiders
- Douglas W. Wilmore
- Erfahrung